PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: tourism industry

COVID-19 rapid antigen self-tests

COVID-19 rapid antigen self-tests Performance requirements and risk mitigation strategies Version , September 2021 Therapeutic Goods Administration COVID-19 self-tests - Performance requirements and risk mitigation strategies - Version , September 2021 Page 2 of 18 Copyright Commonwealth of Australia 2021 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction.

COVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.

Fullscreen Download
Loading..

Tags:

  Rapid

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of COVID-19 rapid antigen self-tests

Documents from same domain

The use of GMDN codes for IVD medical devices in Australia

www.tga.gov.au

Global Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to

  Devices, Medical, Global, Nomenclature, Global medical device nomenclature

AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …

www.tga.gov.au

AUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …

  Information, Product, Name, Product information, Qualitative, Astrazeneca

Australian public assessment report for BNT162b2 (mRNA)

www.tga.gov.au

The RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,

  Lipids, Nanoparticles, Lipid nanoparticles

PE009, the PIC/S guide to GMP for medicinal products

www.tga.gov.au

PE009, the PIC/S guide to GMP for medicinal products: TGA interpretation and expectations for demonstrating compliance V2.1 September 2020 Page 4 of 69 Authorised Person needs full overview of all manufacturing steps ----- 18. RFS includes consideration of marketing authorisation requirements ---- 18

  Medicinal, Needs

Guideline for the labelling of medicines

www.tga.gov.au

Guideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014

  Guidelines, Labelling, Guideline for the labelling

Australian public assessment report for Linagliptin

www.tga.gov.au

• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.

  Assessment, Report, Public, Australian, Public assessment, Australian public assessment report for linagliptin, Linagliptin

Australian Public Assessment Report for Silodosin

www.tga.gov.au

Australian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...

  Assessment, Report, Public, Australian, Ports, Australian public assessment report for silodosin, Silodosin, Public assessment re port

Guidance 18: Impurities in drug substances and …

www.tga.gov.au

Therapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date

  Drug, Impurities, Substance, Impurities in drug substances and, Impurities in drug substances and drug

Explanatory notes for pharmaceutical manufacturers on the ...

www.tga.gov.au

PE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …

  Notes, Pharmaceutical, Life, Manufacturers, Explanatory notes, Explanatory, Explanatory notes for pharmaceutical manufacturers

COMIRNATY™ COVID-19 VACCINE

www.tga.gov.au

Do not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au

  Ingredients, Vaccine

Related documents

Options for the use of rapid antigen tests for COVID-19 JD

www.ecdc.europa.eu

clinical validations of rapid antigen tests. Summary ... Timely and accurate COVID-19 testing is an essential part of surveillance, contact tracing, infection prevention and ... The EU regulatory framework for diagnostic tests Reagents, control materials, testing kits, and instruments intended for medical use are referred to as in vitro ...

  Regulatory, Clinical, Part, Rapid

QAPI TOOLKIT - Medline Industries

www.medline.com

regulatory compliance. Barbara has served on various committees and subcommittees, and has presented at numerous workshops and conventions. As a member of the Centers for Medicare and Medicaid Services (CMS) Technical Expert Panel (TEP), she was part of the QAPI demonstration project. Barbara served as

  Regulatory, Compliance, Industreis, Part, Medline, Regulatory compliance, Medline industries

Center for Clinical Standards and Quality/Survey ...

www.cms.gov

Aug 26, 2020 · Certificate of Compliance (CoC) and Certificate of Registration (CoR) CoC and CoR laboratories will be assessed for compliance with the reporting requirement at 493.1100(a) at the time of an initial, recertification, or complaint survey. Review of a laboratory’s reporting documentation should be incorporated into the routine survey process.

  Clinical, Compliance

EudraVigilance - EVWEB User Manual

www.ema.europa.eu

presentation during all phases of the drug regulatory process (i.e. the pre- and post-authorisation phase). These processes include clinical studies, reports of spontaneous adverse reactions, events, regulatory submissions and regulated product …

  Manual, User, Regulatory, Clinical, Eudravigilance, Eudravigilance evweb user manual, Evweb

The GSPRs (General Safety and Performance Requirements ...

d2evkimvhatqav.cloudfront.net

Manufacturers must now demonstrate compliance with the general safety and performance requirements, the GSPRs, that provide broad, high-level criteria for safety and performance applicable to design, production, and post-production aspects, throughout the lifecycle of all IVDs. Manufacturers that have demonstrated compliance under

  Compliance

Related search queries

Rapid, Clinical, Part, Regulatory, Medline Industries, Regulatory compliance, Compliance, EudraVigilance - EVWEB User Manual